Clinical Scorecard: Hematologic Malignancy Risk With Glucagon-Like Peptide-1 Receptor Agonists: A Multicenter Propensity Score–Matched Study
At a Glance
Category
Detail
Condition
Comparative incidence of newly diagnosed hematologic malignancies among adults with type 2 diabetes initiating GLP-1 receptor agonists versus DPP-4 inhibitors or SGLT2 inhibitors.
Key Mechanisms
Preclinical findings suggest GLP-1RAs may suppress NF-κB signaling and alter immune cell function, effects that could theoretically affect hematopoiesis and lymphomagenesis; clinical evidence remains limited.
Target Population
Adults aged 18 years or older with type 2 diabetes who initiated semaglutide, dulaglutide, liraglutide, or exenatide between January 1, 2015, and March 31, 2021, and met the study’s prescription and diagnosis eligibility criteria.
Care Setting
Retrospective propensity score–matched cohort study using de-identified electronic health records in the TriNetX federated research network.
Key Highlights
The propensity score–matched study compared GLP-1RA users with DPP-4 inhibitor users (68,949 pairs) and SGLT2 inhibitor users (71,391 pairs).
Compared with DPP-4 inhibitors, GLP-1RAs were not associated with statistically significant differences in any assessed hematologic malignancy.
Compared with SGLT2 inhibitors, GLP-1RA use was associated with lower incidence of NHL (HR 0.82), MPN (HR 0.78), and Hodgkin lymphoma (HR 0.52).
No significant differences were found for the other assessed malignancies in the GLP-1RA versus SGLT2 inhibitor comparison or for NHL subtypes in either comparison.
The authors state that the observed associations varied by active comparator.
Guideline-Based Recommendations
Diagnosis
The study assessed newly diagnosed NHL, Hodgkin lymphoma, myeloid and lymphoid leukemias, plasma cell neoplasms, MDS, and MPN.
Management
The article reports comparative observational findings and does not provide treatment recommendations for hematologic malignancies.
Monitoring & Follow-up
Outcomes were evaluated from 180 days after treatment initiation through 5 years using Kaplan–Meier estimation and Cox proportional hazards regression.
Risks
Compared with DPP-4 inhibitors, GLP-1RA use was associated with higher GERD incidence; acute pancreatitis, diabetic ketoacidosis, diarrhea, and constipation did not differ significantly.
Compared with SGLT2 inhibitors, GLP-1RA use was associated with higher GERD, diarrhea, and constipation incidence, lower diabetic ketoacidosis incidence, and no significant difference in acute pancreatitis.
Patient & Prescribing Data
Adults aged 18 years or older with type 2 diabetes documented within the year before the index prescription who initiated a qualifying GLP-1RA, had a subsequent prescription in the same medication class, and had type 2 diabetes documented 1 month to 1 year after the index date.
Clinical trials continue to inform how physicians treat advanced prostate cancer. The American Society of Clinical Oncology (ASCO) develops guidelines to help oncologists evaluate new evidence and apply it to clinical practice
